NCT05567783

A Phase 2 Study to Evaluate the Efficacy and Safety of VIR-2482 for the Prevention of Illness Due to Influenza A

A Double-Blind, Randomized, Placebo-Controlled Phase 2 Study to Evaluate the Efficacy and Safety of VIR-2482 for the Prevention of Illness Due to Influenza A

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 2,977 (actual)
• Sponsor: Vir Biotechnology, Inc. · Industry
• Sex: All
• Age: 18 Years – 64 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to evaluate the efficacy, safety, and tolerability of VIR-2482 compared to placebo in preventing influenza A illness in healthy adults 18 to \<65 years of age without pre-existing risk factors for serious complications from influenza infection.

Conditions

• Influenza A

Interventions

Type	Name	Description
BIOLOGICAL	VIR-2482 (450 mg)	VIR-2482 450mg given by intramuscular injection
BIOLOGICAL	VIR-2482 (1200 mg)	VIR-2482 1200 mg given by intramuscular injection
BIOLOGICAL	Placebo	Sterile 0.9% (w/v) sodium chloride solution given by intramuscular injection

Timeline

• Start date: 2022-10-30
• Primary completion: 2023-05-05
• Completion: 2023-08-31
• First posted: 2022-10-05
• Last updated: 2024-09-19
• Results posted: 2024-09-19

Locations

51 sites across 1 country: United States

Regulatory

• FDA-regulated drug study